Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of single and multiple oral doses of R289 in healthy adults
NL-OMON55213Phase 1Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Sep 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of R289 in autoimmune disease, psoriasis, systemic lupus erythematosus (SLE) and 3 more (4 arms), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of single oral doses of R289 capsules, Safety and tolerability of multiple oral doses of R289 capsules and 4 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
R289
03
Conditions
autoimmune diseasepsoriasissystemic lupus erythematosus (SLE)goutrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON55213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55213.